Abstract:AbstractTriple-negative breast cancers (TNBC) remain clinically challenging with a lack of options for targeted therapy. In this study, we report the development of a second-generation BET protein degrader, BETd-246, which exhibits superior selectivity, potency, and antitumor activity. In human TNBC cells, BETd-246 induced degradation of BET proteins at low nanomolar concentrations within 1 hour of exposure, resulting in robust growth inhibition and apoptosis. BETd-246 was more potent and effective in TNBC cells than its parental BET inhibitor compound BETi-211. RNA-seq analysis revealed predominant downregulation of a large number of genes involved in proliferation and apoptosis in cells treated with BETd-246, as compared with BETi-211 treatment that upregulated and downregulated a similar number of genes. Functional investigations identified the MCL1 gene as a critical downstream effector for BET degraders, which synergized with small-molecule inhibitors of BCL-xL in triggering apoptosis. In multiple murine xenograft models of human breast cancer, BETd-246 and a further optimized analogue BETd-260 effectively depleted BET proteins in tumors and exhibited strong antitumor activities at well-tolerated dosing schedules. Overall, our findings show that targeting BET proteins for degradation represents an effective therapeutic strategy for TNBC treatment. Cancer Res; 77(9); 2476–87. ©2017 AACR.

Supporting Information: Methods from Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer

Supporting Information: Tables from Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer

Supporting Information: Figures from Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure 1 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Materials 2 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Data from Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer

Supplementary Materials 3 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Supplementary Materials & Methods from Targeted Therapy of &Lt;i>tert</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

Supplementary Materials and Methods from Loss of SNAIL Regulated Mir-128-2 on Chromosome 3p22.3 Targets Multiple Stem Cell Factors to Promote Transformation of Mammary Epithelial Cells

Supplementary Materials and Methods, Supplementary Figure Legends, and Supplementary Tables 1 through 5 from SSBP1 Suppresses TGFβ-Driven Epithelial-to-Mesenchymal Transition and Metastasis in Triple-Negative Breast Cancer by Regulating Mitochondrial Retrograde Signaling

Supplementary Materials from Targeting DNA Damage Response Promotes Antitumor Immunity Through STING-Mediated T-cell Activation in Small Cell Lung Cancer

Supplementary Data from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors

Supplementary Materials SM1 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, is Highly Active Against Triple-Negative Breast Cancer

Supplementary Data 1 from Spatiotemporal Quantification of HER2-targeting Antibody–Drug Conjugate Bystander Activity and Enhancement of Solid Tumor Penetration

Supplementary file from Targeting RNA Exonuclease XRN1 Potentiates Efficacy of Cancer Immunotherapy

Supplementary Materials and Methods from An NQO1 Substrate with Potent Antitumor Activity That Selectively Kills by PARP1-Induced Programmed Necrosis

Supplementary Information from A Combinatorial Strategy for Targeting &Lt;i>braf</i><sup>v600e</sup>-Mutant Cancers with BRAF<sup>V600E</sup> Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib)

Supplementary Methods from the CRTC1-NEDD9 Signaling Axis Mediates Lung Cancer Progression Caused by LKB1 Loss